Literature DB >> 24325727

Ultrasound presentation of abdominal tuberculosis in a German tertiary care center.

Thomas von Hahn1, Franz-Christoph Bange, Sandra Westhaus, Kinan Rifai, Dina Attia, Michael Manns, Andrej Potthoff, Michael Gebel.   

Abstract

OBJECTIVE: Abdominal tuberculosis (TB) is a relatively rare disease in most of Europe and the typical clinical and sonographic findings in this setting have not been studied. We aimed to define sonographic findings that should alert an examiner to the possibility of abdominal TB in a low endemic region.
METHODS: Case records of 17 patients with proven (n = 11) or highly likely (n = 6) abdominal TB detected in the gastrointestinal ultrasound unit at a German tertiary care center in 2003-2013 were analyzed retrospectively. Findings were compared with reported series from high-prevalence regions.
RESULTS: While 76% of patients had an immigrant background, only 35% had a condition associated with immunosuppression. Lymphadenopathy was present in all cases of abdominal TB, while it was absent in 28% of patients from a control group with proven abdominal sarcoidosis. Moreover, retroperitoneal lymphadenopathy was significantly more common in TB. Other findings in patients with abdominal TB in descending order of frequency were ascites, altered hepatic texture, splenomegaly, splenic lesions, peritoneal thickening, intestinal wall lesions, hepatic lesions and hepatomegaly. 76% of abdominal TB patients had 2 or more pathological findings.
CONCLUSIONS: Multiple pathological intra-abdominal findings including lymphadenopathy should alert the examiner to the possibility of abdominal TB.

Entities:  

Mesh:

Year:  2013        PMID: 24325727     DOI: 10.3109/00365521.2013.865258

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  1 in total

Review 1.  Hepatic and Intra-abdominal Tuberculosis: 2016 Update.

Authors:  Richard P T Evans; Moustafa Mabrouk Mourad; Lee Dvorkin; Simon R Bramhall
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.